Myanmar Climate-Smart Agriculture Strategy

Myanmar has committed to apply CSA to contribute to regional food security and environmental protection during the 24th ASEAN Summit on May 10, 2014. The Myanmar CSA strategy encompasses the development of technical, policy and investment conditions to achieve a sustainable agricultural development for food security and nutrition through climate-resilient and sustainable agriculture. Myanmar’s CSA strategy aims to be socially, culturally and politically appropriate, environment-friendly and economically feasible to promote and attain sustainable agriculture, food security and nutrition, agricultural development and climate change adaptation and mitigation. Myanmar’s CSA strategy also aims to provide context and analysis for addressing agriculture in international climate negotiations to better inform climate negotiators and other stakeholders by identifying options and unpacking issues of interest

Clinical Profile of Intermediate Syndrome in Organophosphate Poisoning

Organophosphate (OP) poisoning is a major global health problem, causing over 200,000 deaths annually especially in developing countries. In Poison Treatment Center, New Yangon General Hospital, Myanmar, OP poisoning accounts for 14% of total poison admission in 2013, 17% in 2014 and 10.3% in 2015 respectively

Flexible liquid crystal displays

This dissertation describes the fabrication of a plastic substrate for liquid crystal displays (LCDs). Polyimide film, with its transparent substrate, can be used to fabricate the liquid crystal cell. Plastic substrates enjoy such as flexibility, lightweight, bendable for display applications.Master of Science (Photonics

Implementation of Myanmar Character Cryptosystem

Cryptographic algorithm could be used to protectsensitive and valuable data during transmission and in storage.Encryption had been largely the concern of military andintelligence organizations. Among them, Myanmar textinformation is widely used in business, military data and otherorganizations. However, most of cryptosystem are provided forEnglish Language, and Encryption for Myanmar Language isnecessary. And there is no efficient method for MyanmarLanguage yet. Therefore, this paper is an attempt to enable apractical and efficient composing of text information withMyanmar Language on a general purpose computer

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore

Abstract Background Approximately 30–70% of patients who have undergone allogeneic (allo) hematopoietic stem cell transplantation (HSCT) eventually experience chronic graft-versus-host disease (cGVHD). Patients who develop steroid-refractory (SR)-cGVHD are the most severely impacted due to significant disease and financial burden. There remains an unmet need for safe, efficacious, and accessible treatments for these patients. The objective of this study was to determine the cost effectiveness of ruxolitinib for treatment of SR-cGvHD from the Singapore healthcare system perspective. Methods Based on data from the REACH3 randomized open-label trial, a semi-Markov model was developed to evaluate cost-effectiveness of ruxolitinib compared with investigators' choice of best alternative therapy (BAT) for treatment of patients > 12 years of age with SR-cGVHD in Singapore over a 40-year time horizon. The model only considered direct medical-care costs related to the treatment of SR-cGVHD and reported them in Singapore Dollars (SGD). Half-cycle correction was applied to all costs and outcomes, which were discounted at 3%. Probabilistic sensitivity analysis (PSA), one-way sensitivity analysis (OWSA), and scenario analysis were conducted to explore the drivers of uncertainty in the model. Results In the deterministic base case, more life years (LY; 10.28 vs. 9.42) and quality-adjusted life years (QALYs; 7.31 vs. 6.51) were gained with ruxolitinib than BAT at higher costs (SGD 303,214 vs. SGD 302,673) leading to an incremental cost-effectiveness ratio (ICER) of SGD 677/QALY. At a willingness-to-pay threshold of SGD 75,000/QALY gained, PSA found that ruxolitinib had a 78.52% probability of being cost-effective. Findings were sensitive to variations in non-responder utilities in the BAT arm and duration of BAT treatment in the OWSA, or comparison to either methotrexate (MTX) or mycophenolic acid as a single comparator in the scenario analysis. ICERs remained lower than SGD 75,000/QALY in all other tested variations and scenarios. Conclusion Ruxolitinib is likely to be cost-effective from Singapore healthcare system’s perspective for patients with SR-cGVHD, which is promising in the management of patients with unmet clinical needs

BIM Deletion Polymorphism Profiling Complements Prognostic Values of Risk Scores in Imatinib-treated Asian Chronic Myeloid Leukemia Patients

10.1080/10428194.2018.1461863Leukemia & Lymphoma601234-23